Skip to main content
Clinical Trials/NCT06492265
NCT06492265
Recruiting
Phase 2

Emergency Stroke Unit for Acute Cerebrovascular Events--A Prospective, Multicenter, Week-wise Randomized, Controlled Trial ( ESU-ACE-B )

Yongjun Wang1 site in 1 country100 target enrollmentAugust 4, 2024

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Ischemic Stroke, Acute
Sponsor
Yongjun Wang
Enrollment
100
Locations
1
Primary Endpoint
Door-to-puncture time
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

To compare the door-to-puncture time of patients with hyperacute ischemic stroke (between 4.5-6 hours after the onset of symptoms) treated in a standard stroke unit adherent to guidelines versus treated in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).

Detailed Description

Mechanical thrombectomy is an effective reperfusion therapy for patients with acute ischemic stroke due to large vessel occlusion. Faster door-to-puncture time (DPT) is associated with significantly better clinical outcomes. With the development of low-field magnetic resonance imaging, it is poised to play an increasingly significant role in the early diagnosis and management of acute ischemic stroke. This prospective, multicenter, week-wise randomized controlled trial will compare the door-to-puncture time of patients with hyperacute ischemic stroke (between 4.5-6 hours after the onset of symptoms) managed in a standard stroke unit adherent to guidelines versus managed in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).

Registry
clinicaltrials.gov
Start Date
August 4, 2024
End Date
April 1, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Yongjun Wang

professor

Beijing Tiantan Hospital

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years;
  • Can be treated between 4.5-6 hours of symptoms onset\*(\*Symptom onset is defined by the "last seen normal" principle);
  • Presenting with ischemic stroke symptoms;
  • Pre-stroke mRS score 0-1;
  • Baseline NIHSS score ≥ 5;
  • Eligible for endovascular thrombectomy;
  • Informed consent signed.

Exclusion Criteria

  • Baseline NIHSS score \< 5;
  • Unable to undergo MRI because of claustrophobia;
  • Patients with cardiac pacemaker/brain pacemaker/insulin pump implantation;
  • Definite contraindication for endovascular thrombectomy;
  • Patients with postictal hemiparesis (Todd's paralysis) or those with concomitant neurological/psychiatric conditions who are unable or unwilling to cooperate;
  • Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial;
  • Participation in other interventional randomized clinical trials within 3 months before enrollment;
  • Patients deemed unsuitable for participation in this trial by the investigator or those for whom participation in this trial may result in greater risks.

Outcomes

Primary Outcomes

Door-to-puncture time

Time Frame: Door-to-puncture time

The time from emergency department arrival to the puncture of endovascular thrombectomy.

Secondary Outcomes

  • Ordinal (shift) analysis of modified Rankin Scale (mRS) at 14±2 days (or at discharge, whichever occurs first).(at 14±2 days (or at discharge, whichever occurs first).)
  • Good functional outcome (Modified Rankin Scale score, mRS 0-2) at 14±2 days (or at discharge, whichever occurs first).(at 14±2 days (or at discharge, whichever occurs first).)
  • The time from symptoms onset to endovascular thrombectomy decision.(The time from symptoms onset to endovascular thrombectomy decision.)
  • Symptomatic intracranial hemorrhages (according to the ECASS III criteria) within 36 hours.(within 36 hours.)
  • Door-to-reperfusion time(Door-to-reperfusion time)
  • Mortality at 14±2 days (or at discharge, whichever occurs first).(at 14±2 days (or at discharge, whichever occurs first).)
  • The utility-weighted modified Rankin Scale (uw-mRS) at 14±2 days (or at discharge, whichever occurs first).(at 14±2 days (or at discharge, whichever occurs first).)
  • Excellent functional outcome (Modified Rankin Scale score, mRS 0-1) at 14±2 days (or at discharge, whichever occurs first).(at 14±2 days (or at discharge, whichever occurs first).)
  • The time from emergency department arrival to endovascular thrombectomy decision.(The time from emergency department arrival to endovascular thrombectomy decision.)
  • Serious adverse events at 14±2 days (or at discharge, whichever occurs first).(at 14±2 days (or at discharge, whichever occurs first).)
  • Symptomatic intracranial hemorrhages (according to the ECASS III criteria) at 14±2 days (or at discharge, whichever occurs first).(at 14±2 days (or at discharge, whichever occurs first).)
  • Adverse events at 14±2 days (or at discharge, whichever occurs first).(at 14±2 days (or at discharge, whichever occurs first).)

Study Sites (1)

Loading locations...

Similar Trials